Clinical trials: Schizophrenia Patients
- Condition Schizophrenia Patients
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Schizophrenia
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
This study will consist of 2 parts: Part Ⅰ-in healthy adult subjects, Part Ⅱ-in adult patients with schizophrenia
- Trial name
- NCT06504290
- Testing
- VV119 （in healthy adult subjects）, VV119(in adult patients with schizophrenia)
- Where
- 4 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia Disorders
The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects/patients with schizophrenia.
- Trial name
- NCT06674694
- Testing
- Brexpiprazole long-acting injection
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Sichuan Kelun Pharmaceutical Co.,Ltd.
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained…
- Trial name
- NCT00392743
- Testing
- pet/spect scan
- Where
- 7 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Cognitive Impairment Associated With Schizophrenia
Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
The primary purpose of this randomized, double-blind, placebo-controlled cross-over study was to record and measure 40 Hz-auditory steady-state response (ASSR) in healthy controls (HC) and participants with mild-to-moderate…
- Trial name
- NCT05136690
- Testing
- Nicotine patch, MK-4334
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Epilepsy
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
The human brain presents outstanding challenges to science and medicine. Brain function and structure span broad spatial scales (from single neurons to brain-wide networks) as well as temporal scales (from milliseconds to years).
- Conditions
- Healthy, Epilepsy, Psychosis, Essential Tremor
- Trial name
- NCT05769933
- Testing
- Simultaneous EEG-fMRI at 7 Tesla, Structural MRI at 7 Tesla
- Where
- Switzerland
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Psychosis
A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
This is a safety study evaluating the subjects who participated in previous Organon trials of the drug Org 24448. Patients will undergo a Screening visit, 1 or 2 Evaluation visits, and a possible Follow-Up period.
- Trial name
- NCT00780585
- Testing
- SCH 900460
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
First Episode Schizophrenia, Social Function
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
This is an open label, multi-center study to explore the effects on social functions of blonanserin in first episode schizophrenia patients
- Conditions
- First Episode Schizophrenia, Social Function, Cognition Function, Blonanserin
- Trial name
- NCT03784222
- Testing
- Blonanserin, MRI and serum BDNF
- Where
- 8 sites in China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia Disorder
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398
This is an open label study in 2 cohorts of healthy volunteers and 1 cohort of patients with Schizophrenia, designed to evaluate the Dopamine D2 and D3 Receptor Occupancy by SIPI6398 at various doses and timepoints.
- Trial name
- NCT07626034
- Testing
- SIPI6398 Tablets
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongze Therapeutics Co., Ltd.
Schizophrenia
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
This study was designed to compare the [123]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients.
- Trial name
- NCT00364429
- Testing
- [123]I-CNS 1261, Lorazepam, Risperidone
- Where
- Spain
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
This 3-part dose titration study will assess elpipodect safety, tolerability, pharmacokinetics (PK), and central nervous system activity.
- Trial name
- NCT02181803
- Testing
- Elpipodect, Base Monotherapy
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.
The purpose of this study is to understand safety and tolerability of the drug GSK1018921 after 14 days of dosing in healthy volunteers and then in patient volunteers.
- Trial name
- GT1110791 (NCT00929370)
- Testing
- Glycine Transporter-1 inhibitor
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers
The purpose of this study is to measure and contrast implicit and explicit learning performance in patients with schizophrenia relative to young and elderly healthy volunteers.
- Trial name
- NCT01788436
- Testing
- Cognitive Test Battery 1, Cognitive Test Battery 2
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC